Successful treatment of Erdheim-Chester disease, a non–Langerhans-cell histiocytosis, with interferon-α

Fadi Braiteh, Cynthia Boxrud, Bita Esmaeli, and Razelle Kurzrock

Erdheim-Chester disease is a rare non-Langerhans histiocytosis with multisystem involvement. To date, there is no standard treatment for this disorder, and more than half of the patients succumb within 3 years. Because interferon-α promotes the terminal differentiation of histiocytes and dendritic cells, we hypothesized that this molecule would be a useful therapy for Erdheim-Chester disease. We therefore treated 3 patients with advanced disease with interferon-α at a starting dose of 3 to 6 × 10⁶ units, which was later reduced, during maintenance, to 1 × 10⁶ units subcutaneous 3 times per week. Marked improvement was noted in all patients, with substantial retro-orbital disease regression within 1 month. Improvement in bone lesions, pain, diabetes insipidus, and other manifestations was gradual over many months. Responses were durable (3+ to 4.5+ years). Our observations suggest that this well-tolerated therapy has a significant effect on the course and outcome of Erdheim-Chester disease. (Blood. 2005;106:2992-2994)

© 2005 by The American Society of Hematology

Brief report

Introduction

In 1930, William Chester described the first 2 cases of “lipoid granulomatosis,” later renamed Erdheim-Chester disease.1 This illness represents a rare non-Langerhans histiocytosis with particular tropism for connective and adipose tissues. Clinical features range from a focal asymptomatic process to a multisystem, rapidly fatal, infiltrative disease with a total of about 250 cases described in the literature.2-7 Typically, it affects adults of both sexes, with symmetric osteosclerosis of the long bones sparing the epiphyses.2,3 The histiocytes mainly infiltrate bones, pituitary, orbit, retroperitoneum, and central nervous system.2-5 The pathology is characterized by large, foamy, or eosinophilic cytoplasm lipid-laden CD68⁺, CD1a⁺, and S100⁺ histiocytes lacking any Birbeck granules, and the pathognomonic Touton-like giant cells, which are multinucleated cells with the nuclei organized in a wreathlike ring and a xanthomatous cytoplasm.4,6,8

There is no standard treatment for Erdheim-Chester disease. Unfortunately, about 60% of patients succumb to their disease within 32 months of presentation.2 Of interest, researchers reported that interferon-α results in terminal differentiation of histiocytes and dendritic cells.9,10 We therefore administered interferon-α to 3 patients with Erdheim-Chester disease. This treatment resulted in durable responses, with the longest ongoing at 4 years.

Study design

Patient 1

A 55-year-old man with a 4-year history of diabetes insipidus, presented with rapidly decreasing vision, orbital pain, and striking exophthalmos.

Patient 2

A 58-year-old man was evaluated for ongoing leg pain, treated diabetes insipidus, and panhypopituitarism. The long bone radiographs of his legs showed bilateral osteosclerosis of the diaphyses and metaphyses sparing the...
Long bone radiographs revealed a localized area of fibrous sclerosis in the distal left fibula. Computed tomography scans of the abdomen demonstrated retroperitoneal fibrosis. Retro-orbital mass biopsy demonstrated Touton giant cells with CD68+, S100+, and CD1α− histiocytic infiltrate, confirming the diagnosis of Erdheim-Chester disease. The patient’s visual acuity and exophthalmos worsened despite therapy with methotrexate, cyclophosphamide, etoposide, and high-dose prednisone and vincristine.

Interferon-α was started, but the initial dose of $6 \times 10^6$ units subcutaneous 3 times per week was reduced 6 months later to $3 \times 10^6$ units and 4

![Image](image1.png)

**Figure 1. Retro-orbital and retroperitoneal disease in patient 1.** (A) Before interferon-α, extensive retrobulbar soft tissue mass (arrows) is seen on the T1-weighted magnetic resonance imaging before (left) and after (right) gadolinium injection. (B) After 4 years of continuous interferon-α treatment, the extent of retrobulbar infiltration (arrows) continues to decrease substantially. (C) Perinephric adipose tissue reveals large foamy lipid-laden histiocytes with eosinophilic cytoplasm; (ii) staining positive for CD68, (iii) but staining negative for CD1α; and (iv) staining negative for S100 (< 5% positive). Images were acquired at a magnification of 200 × using a Nikon Microphot-FXA microscope (Nikon, Tokyo, Japan) fitted with a 20 × phase-contrast objective lens (PlanApo 20 ×/0.75 NA). Images were captured with a digital camera, model DP-70 (Olympus, Tokyo, Japan), using DP 12 image-acquisition software (Olympus), and image-processing was carried out using Microsoft PowerPoint (Microsoft, Redmond, WA).

Patient 3

A 53-year-old man presented with a bilateral periorbital congestion, erythema, and proptosis. Exophthalmos was confirmed by Hertel exophthalmometry measurements of 27 mm. MRI scan of the orbit showed bilateral intraconal masses with increased signal on T2-weighted images.

![Image](image2.png)

**Figure 2. Response to interferon-α in patients 2 and 3.** (A) Morphine equivalent daily dose (MEDD; mg/d) needed to manage pain before and after interferon-α therapy. Patient required 120 mg/d opioids before starting interferon-α. After 2 years, he no longer needs opioids. (B) Bone radiograph of the right femur reveals mixed osteosclerotic and osteolytic lesions before treatment. Ongoing improvement is seen after 2 years of treatment with interferon-α. (C) (Top) Bilateral exophthalmos with chemosis, engorged conjunctival vessels, and inferior scleral show (arrows) at presentation. Loss of eyelashes because of recent chemotherapy is noted. (Bottom) Exophthalmos, chemosis, and inferior scleral show (arrows) resolved after 2 years of interferon-α. Eyelashes have grown back.
months afterward to \(1 \times 10^6\) units because of fatigue. The patient tolerated low-dose interferon-\(\alpha\) well and continued on it for an additional 16 months. Therapy was stopped because the patient’s eye examination had normalized (Figure 2C). Eight months later, new skin lesions were noted, and biopsy confirmed relapse. Interferon-\(\alpha\) was recently restarted, and the patient again demonstrated response.

Approval was obtained from the University of Texas MD Anderson Cancer Center institutional review board for these studies. Informed consent was provided in accordance with the Declaration of Helsinki.

Results and discussion

Erdheim-Chester disease is a rare non-Langerhans histiocytosis of unknown etiology. The outcome of patients with Erdheim-Chester disease is worse than that for Langerhans-cell histiocytosis with 59% of patients in the former group dead after a mean follow-up of 32 months, whereas only 9% of patients with the latter disorder have succumbed after a median follow-up of 4 years.

Numerous treatments have been attempted for this disease. Corticosteroids are the traditional first-line treatment and are used to control symptoms, but generally they are either ineffective or only transiently effective. Bisphosphonates are often effective in treating osteolytic lesions in Langerhans-cell histiocytosis but have only partial or temporary success in the management of bone involvement in Erdheim-Chester disease. Chemotherapy can induce transient partial responses but is often ineffective. Cladribine has been used successfully in adult Langerhans histiocytosis, but its application in Erdheim-Chester disease is limited to 2 patients, one of whom responded. Radiation, methotrexate, cyclophosphorine, and azathioprine have not yielded sustained clinical response.

We describe the successful treatment of 3 patients with Erdheim-Chester disease with interferon-\(\alpha\). The initial therapeutic dose of 3 to \(6 \times 10^6\) units subcutaneous 3 times per week was reduced to \(1 \times 10^6\) units 3 times per week because of fatigue. This low dose was well tolerated, and response was observed within 1 month with dramatic reduction in the exophthalmos and recovery of vision in 2 patients (cases 1 and 3) whose vision was threatened by progressive disease while on high-dose chemotherapy and/or steroids. Response was also manifested by gradual improvement in diabetes insipidus (cases 1 and 2) and in bone lesions (case 2) (Figure 2).

The mechanism(s) underlying the salutary effects of interferon-\(\alpha\) in Erdheim-Chester are unclear but could be due to several of the diverse biologic effects of this agent: maturation and activation of dendritic cells, immune-mediated (eg, via natural killer cells) destruction of histiocytes, or direct antiproliferative effects. There is also anecdotal evidence of clinical therapeutic benefits for interferon-\(\alpha\) in other histiocytic disorders (Langerhans-cell histiocytosis and Rosai-Dorfman disease).

Erdheim-Chester disease is a rare and difficult-to-treat disease. All 3 of our patients with this disorder achieved a long-lasting response (3+, 3.5, and 4.5+ years) while receiving interferon-\(\alpha\). Our observations suggest that this well-tolerated treatment warrants further application and investigation in this disorder.

References

Successful treatment of Erdheim-Chester disease, a non–Langerhans-cell histiocytosis, with interferon-α

Fadi Braiteh, Cynthia Boxrud, Bita Esmaeli and Razelle Kurzrock